Advertisement

Detoxification Functions of the Liver

  • Udayan Apte
  • Partha Krishnamurthy
Chapter
Part of the Molecular Pathology Library book series (MPLB, volume 5)

Abstract

The body is exposed to a variety of chemicals everyday in the form of pharmaceutical agents, household chemicals, dietary supplements, and environmental contaminants, many of which are extremely toxic. The primary defense mechanisms against xenobiotics in the body are the drug metabolizing enzymes (DMEs) involved in metabolism and excretion of xenobiotics [1]. Liver is the primary organ involved in the metabolism of xenobiotics including chemicals and pharmaceutical agents. Other organs including kidney and intestine have minor drug metabolism capabilities but liver is the site of metabolism for a vast majority of drugs and chemicals [2]. The chemical reactions involved in drug metabolism generally convert chemicals into more water-soluble metabolites rendering them easier for eventual excretion in the urine. Whereas many reactions catalyzed by the DMEs result in more water-soluble products, which are relatively less harmful, a number of the DME-mediated reactions result in the production of metabolic intermediates, which are highly reactive and induce tissue damage [3]. Therefore, the detoxification function of the liver is not homogenous and metabolism of each chemical in the liver should be investigated on a case-by-case basis. Nevertheless, there are some general principles that apply to the entire drug metabolism process.

Keywords

CYP450 Enzyme Aromatic Hydrocarbon Receptor Constitutive Androstane Receptor Conjugation Reaction Canalicular Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Williams RT. Detoxification mechanism: the metabolism and detoxification of drugs, toxic substances, and other organic compounds. 2nd ed. New York: Wiley; 1959.Google Scholar
  2. 2.
    Parkinson A, Ogilvie BW. Biotransformation of Xenobiotics. In: Klaassen CD, editor. Casarett and Doull’s toxicology: the basic science of poisons. 7th ed. New York: McGraw-Hill; 2008. p. 161–304.Google Scholar
  3. 3.
    Williams JA, Hurst SI, Bauman J, et al. Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab. 2003;4(6):527–34.PubMedGoogle Scholar
  4. 4.
    Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci. 2006;89(1):31–41.PubMedGoogle Scholar
  5. 5.
    Bruning T, Bolt HM. Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies. Crit Rev Toxicol. 2000;30(3):253–85.PubMedGoogle Scholar
  6. 6.
    Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol Sci. 2008;101(2):186–96.PubMedGoogle Scholar
  7. 7.
    Guengerich FP, Hosea NA, Parikh A, et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos. 1998;26(12):1175–8.PubMedGoogle Scholar
  8. 8.
    Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002;181–182:447–52.PubMedGoogle Scholar
  9. 9.
    Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.PubMedGoogle Scholar
  10. 10.
    Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279(23):23847–50.PubMedGoogle Scholar
  11. 11.
    Audet-Walsh E, Auclair-Vincent S, Anderson A. Glucocorticoids and phenobarbital induce murine CYP2B genes by independent mechanisms. Expert Opin Drug Metab Toxicol. 2009;5(12):1501–11.PubMedGoogle Scholar
  12. 12.
    Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009;10(6):567–78.PubMedGoogle Scholar
  13. 13.
    Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23–37.PubMedGoogle Scholar
  14. 14.
    Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol. 2004;44:27–42.PubMedGoogle Scholar
  15. 15.
    Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389–430.PubMedGoogle Scholar
  16. 16.
    Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1–17.PubMedGoogle Scholar
  17. 17.
    Johnson EF, Hsu MH, Savas U, Griffin KJ. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology. 2002;181–182:203–6.PubMedGoogle Scholar
  18. 18.
    Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol. 2006;46:41–64.PubMedGoogle Scholar
  19. 19.
    Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology. 2000;31(2):255–60.PubMedGoogle Scholar
  20. 20.
    Apte U, Singh S, Zeng G, et al. Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. Am J Pathol. 2009;175(3):1056–65.PubMedGoogle Scholar
  21. 21.
    Benhamouche S, Decaens T, Godard C, et al. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev Cell. 2006;10(6):759–70.PubMedGoogle Scholar
  22. 22.
    Ziegler DM. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab Rev. 2002;34(3):503–11.PubMedGoogle Scholar
  23. 23.
    Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581–616.PubMedGoogle Scholar
  24. 24.
    Mudler GJ. Sulfation of drugs and related compounds. Boca Raton: CRC; 1981.Google Scholar
  25. 25.
    Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol. 1990;30:603–31.PubMedGoogle Scholar
  26. 26.
    Sim E, Lack N, Wang CJ, et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology. 2008;254(3):170–83.PubMedGoogle Scholar
  27. 27.
    Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 2003;17(1–4):103–14.PubMedGoogle Scholar
  28. 28.
    Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A. 1999;96(12):6914–9.PubMedGoogle Scholar
  29. 29.
    Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 2002;82(2):193–201.PubMedGoogle Scholar
  30. 30.
    Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 2000;60(18):5269–77.PubMedGoogle Scholar
  31. 31.
    Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology. 2001;33(4):783–91.PubMedGoogle Scholar
  32. 32.
    Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999;274(21):15181–5.PubMedGoogle Scholar
  33. 33.
    Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999;59(23):5964–7.PubMedGoogle Scholar
  34. 34.
    Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001;61(19):7225–32.PubMedGoogle Scholar
  35. 35.
    Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000;60(17):4779–84.PubMedGoogle Scholar
  36. 36.
    Li T, Ito K, Horie T. Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003;285(3):G602–10.PubMedGoogle Scholar
  37. 37.
    Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002;19(1):34–41.PubMedGoogle Scholar
  38. 38.
    Manautou JE, de Waart DR, Kunne C, et al. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology. 2005;42(5):1091–8.PubMedGoogle Scholar
  39. 39.
    Kuroda M, Kobayashi Y, Tanaka Y, et al. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol. 2004;19(2):146–53.PubMedGoogle Scholar
  40. 40.
    Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos. 2005;33(7):956–62.PubMedGoogle Scholar
  41. 41.
    Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J Pharmacol Exp Ther. 2006;317(2):537–45.PubMedGoogle Scholar
  42. 42.
    Sampath J, Adachi M, Hatse S, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.PubMedGoogle Scholar
  43. 43.
    Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003;38(2):374–84.PubMedGoogle Scholar
  44. 44.
    Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem. 2004;279(21):22250–7.PubMedGoogle Scholar
  45. 45.
    Zelcer N, Reid G, Wielinga P, et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003;371(Pt 2):361–7.PubMedGoogle Scholar
  46. 46.
    Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G640–9.PubMedGoogle Scholar
  47. 47.
    Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001;276(36):33747–54.PubMedGoogle Scholar
  48. 48.
    Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001;276(42):39411–8.PubMedGoogle Scholar
  49. 49.
    Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007;1773(3):283–308.PubMedGoogle Scholar
  50. 50.
    Tanaka Y, Kobayashi Y, Gabazza EC, et al. Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice. Am J Physiol Gastrointest Liver Physiol. 2002;282(4):G656–62.PubMedGoogle Scholar
  51. 51.
    Maher JM, Aleksunes LM, Dieter MZ, et al. Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci. 2008;106(2):319–28.PubMedGoogle Scholar
  52. 52.
    Donner MG, Warskulat U, Saha N, Haussinger D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol Chem. 2004;385(3–4):331–9.PubMedGoogle Scholar
  53. 53.
    Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000;97(13):7476–81.PubMedGoogle Scholar
  54. 54.
    Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000;57(3):634–41.PubMedGoogle Scholar
  55. 55.
    Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002;62(21):6172–7.PubMedGoogle Scholar
  56. 56.
    Ilias A, Urban Z, Seidl TL, et al. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002;277(19):16860–7.PubMedGoogle Scholar
  57. 57.
    Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci. 2003;92(9):1739–53.PubMedGoogle Scholar
  58. 58.
    Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev. 2001;46(1–3):89–102.PubMedGoogle Scholar
  59. 59.
    Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40(suppl):S3–8.PubMedGoogle Scholar
  60. 60.
    Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today. 2007;12(19–20):838–43.PubMedGoogle Scholar
  61. 61.
    Li X, Li JP, Yuan HY, et al. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol. 2007;29(9):607–17.PubMedGoogle Scholar
  62. 62.
    Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006;1(3):323–39.PubMedGoogle Scholar
  63. 63.
    Panczyk M, Salagacka A, Mirowski M. MDR1 (ABCB1) gene encoding glycoprotein P (P-gp), a member of ABC transporter superfamily: consequences for therapy and progression of neoplastic diseases. Postepy Biochem. 2007;53(4):361–73.PubMedGoogle Scholar
  64. 64.
    Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci. 2006;256(5):281–6.PubMedGoogle Scholar
  65. 65.
    Smith AJ, Timmermans-Hereijgers JL, Roelofsen B, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett. 1994;354(3):263–6.PubMedGoogle Scholar
  66. 66.
    Deleuze JF, Jacquemin E, Dubuisson C, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology. 1996;23(4):904–8.PubMedGoogle Scholar
  67. 67.
    Dixon PH, Weerasekera N, Linton KJ, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet. 2000;9(8):1209–17.PubMedGoogle Scholar
  68. 68.
    Arrese M, Ananthanarayanan M. The bile salt export pump: molecular properties, function and regulation. Pflugers Arch. 2004;449(2):123–31.PubMedGoogle Scholar
  69. 69.
    Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002;123(5):1649–58.PubMedGoogle Scholar
  70. 70.
    Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223–31.PubMedGoogle Scholar
  71. 71.
    Funk C, Pantze M, Jehle L, et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001;167(1):83–98.PubMedGoogle Scholar
  72. 72.
    Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118(2):422–30.PubMedGoogle Scholar
  73. 73.
    Jansen PL, Strautnieks SS, Jacquemin E, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999;117(6):1370–9.PubMedGoogle Scholar
  74. 74.
    Keitel V, Burdelski M, Warskulat U, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology. 2005;41(5):1160–72.PubMedGoogle Scholar
  75. 75.
    Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol. 2001;59(3):627–35.PubMedGoogle Scholar
  76. 76.
    Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol. 2006;44(6):1150–7.PubMedGoogle Scholar
  77. 77.
    Shoda J, Kano M, Oda K, et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol. 2001;96(12):3368–78.PubMedGoogle Scholar
  78. 78.
    Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33(3):633–46.PubMedGoogle Scholar
  79. 79.
    Siewert E, Dietrich CG, Lammert F, et al. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun. 2004;322(1):232–8.PubMedGoogle Scholar
  80. 80.
    Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol. 2007;47(5):566–78.PubMedGoogle Scholar
  81. 81.
    Tanaka T, Uchiumi T, Hinoshita E, et al. The human multidrug resistance protein 2 gene: functional characterization of the 5′-flanking region and expression in hepatic cells. Hepatology. 1999;30(6):1507–12.PubMedGoogle Scholar
  82. 82.
    Keppler D, Konig J, Buchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzyme Regul. 1997;37:321–33.PubMedGoogle Scholar
  83. 83.
    Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000;57(4):760–8.PubMedGoogle Scholar
  84. 84.
    Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003;278(26):23529–37.PubMedGoogle Scholar
  85. 85.
    Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, Evers R. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther. 2004;309(1):156–64.PubMedGoogle Scholar
  86. 86.
    Keppler D, Konig J. Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 1997;11(7):509–16.PubMedGoogle Scholar
  87. 87.
    Meier PJ. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am J Physiol. 1995;269(6 Pt 1):G801–12.PubMedGoogle Scholar
  88. 88.
    Hashimoto K, Uchiumi T, Konno T, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology. 2002;36(5):1236–45.PubMedGoogle Scholar
  89. 89.
    Iyanagi T, Emi Y, Ikushiro S. Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. Biochim Biophys Acta. 1998;1407(3):173–84.PubMedGoogle Scholar
  90. 90.
    Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology. 2000;32(6):1317–28.PubMedGoogle Scholar
  91. 91.
    Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet. 1999;64(3):739–46.PubMedGoogle Scholar
  92. 92.
    Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver. 2001;21(4):247–53.PubMedGoogle Scholar
  93. 93.
    Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer. 2001;94(4):492–9.PubMedGoogle Scholar
  94. 94.
    Geier A, Dietrich CG, Voigt S, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005;289(5):G831–41.PubMedGoogle Scholar
  95. 95.
    Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 2006;46:381–410.PubMedGoogle Scholar
  96. 96.
    Enokizono J, Kusuhara H, Sugiyama Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos. 2007;35(2):209–14.PubMedGoogle Scholar
  97. 97.
    Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001;288(4):827–32.PubMedGoogle Scholar
  98. 98.
    Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003;278(25):22644–9.PubMedGoogle Scholar
  99. 99.
    Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther. 2006;319(1):459–67.PubMedGoogle Scholar
  100. 100.
    Lu K, Lee MH, Yu H, et al. Molecular cloning, genomic organization, genetic variations, and characterization of murine sterolin genes Abcg5 and Abcg8. J Lipid Res. 2002;43(4):565–78.PubMedGoogle Scholar
  101. 101.
    Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem. 2003;278(48):48275–82.PubMedGoogle Scholar
  102. 102.
    Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J Mol Med. 2002;80(5):271–81.PubMedGoogle Scholar
  103. 103.
    Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277(21):18793–800.PubMedGoogle Scholar
  104. 104.
    Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–5.PubMedGoogle Scholar
  105. 105.
    Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994;93(3):1326–31.PubMedGoogle Scholar
  106. 106.
    Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339(17):1217–27.PubMedGoogle Scholar
  107. 107.
    Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis. 2000;20(3):373–84.PubMedGoogle Scholar
  108. 108.
    Petzinger E, Wickboldt A, Pagels P, Starke D, Kramer W. Hepatobiliary transport of bile acid amino acid, bile acid peptide, and bile acid oligonucleotide conjugates in rats. Hepatology. 1999;30(5):1257–68.PubMedGoogle Scholar
  109. 109.
    Kullak-Ublick GA, Glasa J, Boker C, et al. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology. 1997;113(4):1295–305.PubMedGoogle Scholar
  110. 110.
    Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995;109(4):1274–82.PubMedGoogle Scholar
  111. 111.
    Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003;1609(1):1–18.PubMedGoogle Scholar
  112. 112.
    Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251–60.PubMedGoogle Scholar
  113. 113.
    Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274(52):37161–8.PubMedGoogle Scholar
  114. 114.
    Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120(2):525–33.PubMedGoogle Scholar
  115. 115.
    Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999;274(24):17159–63.PubMedGoogle Scholar
  116. 116.
    Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000;278(1):G156–64.PubMedGoogle Scholar
  117. 117.
    Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem. 2001;276(40):37206–14.PubMedGoogle Scholar
  118. 118.
    Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001;120(7):1689–99.PubMedGoogle Scholar
  119. 119.
    Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000;275(30):23161–8.PubMedGoogle Scholar
  120. 120.
    Nagase T, Ishikawa K, Suyama M, et al. Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1998;5(6):355–64.PubMedGoogle Scholar
  121. 121.
    Buesen R, Mock M, Seidel A, Jacob J, Lampen A. Interaction between metabolism and transport of benzo[a]pyrene and its metabolites in enterocytes. Toxicol Appl Pharmacol. 2002;183(3):168–78.PubMedGoogle Scholar
  122. 122.
    Zelcer N, Huisman MT, Reid G, et al. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003;278(26):23538–44.PubMedGoogle Scholar
  123. 123.
    Ji B, Ito K, Suzuki H, Sugiyama Y, Horie T. Multidrug resistance-associated protein2 (MRP2) plays an important role in the biliary excretion of glutathione conjugates of 4-hydroxynonenal. Free Radic Biol Med. 2002;33(3):370–8.PubMedGoogle Scholar
  124. 124.
    Letourneau IJ, Bowers RJ, Deeley RG, Cole SP. Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. Toxicol Lett. 2005;157(1):9–19.PubMedGoogle Scholar
  125. 125.
    Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci. 2003;92(6):1250–61.PubMedGoogle Scholar
  126. 126.
    Cui Y, Konig J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol. 2001;60(5):934–43.PubMedGoogle Scholar
  127. 127.
    Wortelboer HM, Usta M, van der Velde AE, et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 2003;16(12):1642–51.PubMedGoogle Scholar
  128. 128.
    Matsushima S, Maeda K, Kondo C, et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005;314(3):1059–67.PubMedGoogle Scholar
  129. 129.
    Spears KJ, Ross J, Stenhouse A, et al. Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005;69(3):415–23.PubMedGoogle Scholar
  130. 130.
    Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002;277(8):6497–503.PubMedGoogle Scholar
  131. 131.
    Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, Cole SP. Transport of the beta -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem. 2001;276(30):27846–54.PubMedGoogle Scholar
  132. 132.
    Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J. 2003;369(Pt 1):23–30.PubMedGoogle Scholar
  133. 133.
    Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001;276(49):46400–7.PubMedGoogle Scholar
  134. 134.
    Lee YM, Cui Y, Konig J, et al. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics. 2004;14(4):213–23.PubMedGoogle Scholar
  135. 135.
    Paumi CM, Wright M, Townsend AJ, Morrow CS. Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12, 14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003;42(18):5429–37.PubMedGoogle Scholar
  136. 136.
    Lee YJ, Kusuhara H, Sugiyama Y. Do multidrug resistance-associated protein-1 and -2 play any role in the elimination of estradiol-17 beta-glucuronide and 2, 4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier? J Pharm Sci. 2004;93(1):99–107.PubMedGoogle Scholar
  137. 137.
    Liu J, Chen H, Miller DS, et al. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol. 2001;60(2):302–9.PubMedGoogle Scholar
  138. 138.
    Zelcer N, van de Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A. 2005;102(20):7274–9.PubMedGoogle Scholar
  139. 139.
    van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595–603.PubMedGoogle Scholar
  140. 140.
    Klokouzas A, Wu CP, van Veen HW, Barrand MA, Hladky SB. cGMP and glutathione-conjugate transport in human erythrocytes. Eur J Biochem. 2003;270(18):3696–708.PubMedGoogle Scholar
  141. 141.
    Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62(11):3144–50.PubMedGoogle Scholar
  142. 142.
    Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem. 2003;278(20):17664–71.PubMedGoogle Scholar
  143. 143.
    Bai J, Lai L, Yeo HC, Goh BC, Tan TM. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004;36(2):247–57.PubMedGoogle Scholar
  144. 144.
    Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis. 2005;26(10):1754–63.PubMedGoogle Scholar
  145. 145.
    Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003;64(3):610–8.PubMedGoogle Scholar
  146. 146.
    Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004;279(23):24218–25.PubMedGoogle Scholar
  147. 147.
    Yoshikawa M, Ikegami Y, Hayasaka S, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004;110(6):921–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pharmacology, Toxicology and TherapeuticsUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations